Radiolabeling and in vitro evaluation of 67Ga-NOTA-modular nanotransporter - A potential Auger electron emitting EGFR-targeted radiotherapeutic

Nuclear Medicine and Biology

Volumn 41, Issue 6, 2014, Pages 441-449

  Koumarianou, Eftychia ^a   Slastnikova, Tatiana A ^b,c   Pruszynski, Marek ^a   Rosenkranz, Andrey A ^b,c   Vaidyanathan, Ganesan ^a   Sobolev, Alexander S ^b,c   Zalutsky, Michael R ^a,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUTE OF GENE BIOLOGY   (Russian Federation)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Auger electron emitter; EGFR; Modular nanotransporter; Radionuclide therapy

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID BOVINE SERUM ALBUMIN GA 67; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID EDETIC ACID GA 67; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID EPIDERMAL GROWTH FACTOR GA 67; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID MODULAR NANOTRANSPORTER GA 67; BOVINE SERUM ALBUMIN; EDETIC ACID; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GALLIUM CHLORIDE; MODULAR NANOTRANSPORTER; POLYPEPTIDE; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; 2-(4-ISOTHIOCYANATOBENZYL)-1,4,7-TRIAZACYCLONONANE-1,4,7-TRIACETIC ACID; GALLIUM; HETEROCYCLIC COMPOUND; ISOTHIOCYANIC ACID DERIVATIVE; PEPTIDE;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; CELL KILLING; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DOSIMETRY; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SCREENING; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; ISOTOPE LABELING; PH; PRECIPITATION; RADIATION DOSE; RADIOACTIVITY; RADIOTHERAPY; CHEMISTRY; ELECTRON; GENE EXPRESSION REGULATION; METABOLISM; PROCEDURES; PROTEIN TRANSPORT; RADIOMETRY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL NUCLEUS; ELECTRONS; GALLIUM RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS; HUMANS; ISOTHIOCYANATES; ISOTOPE LABELING; PEPTIDES; PROTEIN TRANSPORT; RADIOMETRY; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84901290282     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.03.026     Document Type: Article

References (39)

1. Buchegger F., Perillo-Adamer F., Dupertuis Y.M., Delaloye A.B. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging 2006, 33:1352-1363.
2. Cornelissen B., Vallis K.A. Targeting the Nucleus: an overview of Auger-Electron Radionuclide therapy. Curr Drug Discov Technol 2010, 7:263-279.
3. Pouget J.P., Santoro L., Raymond L., Chouin N., Bardiès M., Bascoul-Mollevi C., et al. Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by Auger electrons. Radiat Res 2008, 170:192-200.
4. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 2000, 41:429-438.
5. Hofer K.G., Harris C.R., Smith M.J. Radiotoxicity of intracellular Ga-67, I-125 and H-3: nuclear versus cytoplasmic radiation effects in murine L1210 leukemia cells. Int J Radiat Biol Relat Stud Phys Chem Med 1975, 28:225-241.
6. Goddu S.M., Howell R.W., Bouchet L.G., Bolch W.E., Rao D.V. MIRD cellular S values 1997, Society of Nuclear Medicine, Reston, V.A.
7. 211At. Int J Radiat Oncol Biol Phys 2008, 72:193-200.
8. 111In in human myeloid leukemia cells. J Nucl Med 2006, 47:827-836.
9. 111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequence (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007, 48:1357-1368.
10. Yarden Y., Sliwkowski M.X. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
11. Hatanpaa K.J., Burma S., Zhao D., Habib A.A. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010, 12:675-684.
12. Rosenkranz A.A., Lunin V.G., Gulak P.V., Sergienko O.V., Shumiantseva M.A., Voronina O.L., et al. Recombinant modular transporters for cell-specific nuclear delivery of locally acting drugs enhance photosensitizer activity. FASEB J 2003, 17:1121-1123.
13. Slastnikova T.A., Rosenkranz A.A., Gulak P.V., Schiffelers R.M., Lupanova T.N., Khramtsov Y.V., et al. Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery. Int J Nanomedicine 2012, 7:467-482.
14. 125I. EJNMMI Res 2012, 2:59-69.
15. 67Ga-labelled antibody via 1B4M or C-NOTA chelates. Nucl Med Biol 1997, 24:225-230.
16. Gilyazova D.G., Rosenkranz A.A., Gulak P.V., Lunin V.G., Sergienko O.V., Khramtsov Y.V., et al. Targeting cancer cells by novel engineered modular transporters. Cancer Res 2006, 66:10534-10540.
17. 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 2010, 37:741-750.
18. 211At]astato-3-pyridinecarboxylate. Nucl Med Biol 1999, 26:405-411.
19. Zalutsky M.R., Boskovitz A., Kuan C.-T., Pegram C.N., Ayriss J., Wikstrand C.J., et al. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nucl Med Biol 2012, 39:23-34.
20. Lo H.W., Hsu S.-C., Wei Y., Bartolomeusx G., Shih J.-Y., Hung M.C. Nuclear interaction of EGFR and STAT3 in the activation of iNOS/NO pathway. Cancer Cell 2005, 6:575-589.
21. Karagiannis T.C. Antibody-based cancer treatment with ultra-short range Auger electron-emitting radionuclides: Dual receptor and DNA targeting strategies. Hell J Nucl Med 2007, 10:155-159.
22. Howell R.W. Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM. Nuclear Medicine Task Group No. 6. Med Phys 1992, 19:1371-1383.
23. Heeg M.J., Jurisson S.S. The role of inorganic chemistry in the development of radiometal agents for cancer therapy. Acc Chem Res 1993, 32:1050-1060.
24. 111Indium-1,4,7,10-tetraazacyclododecane-N, N', N", N"'-tetraacetic acid (DOTA). Chelates for radioimmunodiagnosis and therapy. Cancer Res 1995, 55:5726s-5728s. [Suppl].
25. Wangler C., Schirrmacher R., Bertenstein P., Wangler B. Simple and convenient radiolabeling of proteins using a prelabeling-approach with thiol-DOTA. Bioorg Med Chem Lett 2009, 19:1926-1929.
26. 68Ga-labeled Annexin A5 as a PET imaging agent for apoptosis. Nucl Med Biol 2011, 38:381-392.
27. 67Ga in the preparation of antibody conjugates. Nucl Med Biol 2005, 32:513-519.
28. Stein R., Govindan S.V., Mattes M.J., Chen S., Reed L., Newsome G., et al. Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res 2003, 63:111-118.
29. Vaidyanathan G., Zalutsky M.R. Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides. Nat Protoc 2007, 2:282-286.
30. 131I]SGMIB). Bioconjug Chem 2001, 12:428-438.
31. 111In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer. Breast Cancer Res Treat 2012, 135:189-200.
32. Reits E.A., Benham A.M., Plougastel B., Neefjes J., Trowsdale J. Dynamics of proteasome distribution in living cells. EMBO J 1997, 16:6087-6094.
33. Govindan S.V., Goldenberg D.M., Elsarma S.E., Griffiths G.L., Ong G.L., Brechbiel M.W., et al. Radionuclides linked to CD74 antibody as therapeutic agents for B-Cell lymphoma: comparison of Auger electron emitters with β-particle emitters. J Nucl Med 2000, 41:2089-2097.
34. Shih L.B., Thorpe S.R., Griffiths G.L., Diril H., Ong G.L., Hansen H.J., et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 1994, 35:899-908.
35. Michel R.B., Brechbiel M.W., Mattes M.J. A comparison of 4 radionuclides conjugates to antibodies for single-cell kill. J Nucl Med 2003, 44:632-640.
36. Seymour C.B., Mothersill C. Relative contribution and targeted cell killing to the low-dose region of the radiation dose-response curve. Radiat Res 2000, 153:508-511.
37. Little J.B., de Azzam E.I., Toledo S.M., Nagasawa H. Bystander effects: intracellular transmission of radiation damage signals. Radiat Prot Dosimetry 2002, 99:159-162.
38. Boyd M., Ross S.C., Dorrens J., Fullerton N.E., Tan K.W., Zalutsky M.R., et al. Radiation-induced biological bystander effect elicited in vitro by radiopharmaceuticals labeled with α-, β- and Auger electron-emitting radionuclides. J Nucl Med 2006, 47:1007-1015.
39. Xue L.Y., Butler N.J., Makrigiorgos G.M., Adelstein S.J., Kassis A.I. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci U S A 2002, 99:13765-13770.